Goldman Sachs Starts Exelixis (EXEL) at Neutral
Tweet
Share
E-mailGet Alerts EXEL Hot Sheet
Price: $51.24 +1.24%
Rating Summary:
14 Buy, 12 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
14 Buy, 12 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Goldman Sachs initiates coverage on Exelixis (NASDAQ: EXEL) with a Neutral and $13 price target.
The analyst said the key driver for the shares is oral cancer drug Cabo, however they believe positive Phase 2 Cabo data is already priced in.
For more ratings news on Exelixis click here and for the rating history of Exelixis click here.
Shares of Exelixis closed at $12.36 yesterday.
The analyst said the key driver for the shares is oral cancer drug Cabo, however they believe positive Phase 2 Cabo data is already priced in.
For more ratings news on Exelixis click here and for the rating history of Exelixis click here.
Shares of Exelixis closed at $12.36 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mesoblast completes patient treatment in phase 3 back pain trial
- Axis Capital Limited Assumes Jubilant Foodworks Ltd (JUBI:IN) at Reduce (3)
- JPMorgan Resumes SanDisk (SNDK) at Overweight
Create E-mail Alert Related Categories
FDA, New CoverageRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
